The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Sutro Biopharma, Inc. announced a strategic shift focusing on its next-generation exatecan and dual-payload antibody drug conjugate (ADC) programs, deprioritizing the development of luveltamab ...
SOT109 leverages exatecan-based payload to produce potential best-in-class ADC for validated CDH17 target SOT109 expected to enter a first-in-human Phase 1 clinical trial in 2026 SOTIO Biotech, a ...
• Data underscores ability of Synaffix’s technologies to enable best in class, next generation ADCs AMSTERDAM, NETHERLANDS, 13th October 2021 — Synaffix B.V., a biotechnology company focused on ...
- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile - SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results